Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial.
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Briefing desk at Markets Brief (2026-09-30): Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial. Primary source: original at Nasdaq Market Structure (nasdaq.com).